Cisterna Biologics specializes in the development and production of high-purity RNA products, leveraging advanced technologies to enhance the quality and functionality of RNA for research, diagnostics, and therapeutic applications. By addressing critical challenges in RNA production—such as impurities, scalability, and cost—Cisterna empowers researchers and clinicians to harness the full potential of RNA-based solutions. Key Features and Functionality: - Prime RNA: Utilizes molecular engineering techniques, including tethering and blocking, to produce RNA molecules with precise lengths (ranging from 16 nucleotides to several thousand) and consistent 3' ends, ensuring reliable performance across various research and development applications. - SPECC (SPEcific Capture and Cleavage) Platform: A proprietary technology designed to synthesize mRNA free from common contaminants such as double-stranded RNA (dsRNA), short truncated RNA (stRNA), and long RNA impurities (LRNA). This platform is particularly tailored for immune-silent therapeutic applications, providing exceptionally pure mRNAs suitable for demanding initiatives. - Custom RNA Synthesis: Offers on-demand synthesis of custom RNA sequences, allowing researchers to obtain RNA tailored to their specific experimental needs with selectable purity and quantity options. Primary Value and Solutions Provided: Cisterna Biologics addresses the multifaceted challenges inherent in RNA production, including quality, quantity, cost, and delivery lead time. By employing cutting-edge chemistry and biochemistry, the company produces RNA with enhanced purity and functionality, eliminating impurities that can compromise the efficacy of downstream applications. This commitment to high-quality RNA production enables more effective applications in gene editing, protein expression, and other advanced biotechnological solutions, ultimately advancing the field of RNA-based research and therapeutics.